ArticleSkin health and disease2025
Epidemiology, clinical characteristics, flares and mortality of generalized pustular psoriasis: a nationwide register study in Finland.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of spesolimab in patients with generalized pustular psoriasis flares: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Economic Burden of Generalized Pustular Psoriasis: A Population-based Register Study in Finland.Acta dermato-venereologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Generalized pustular psoriasis (GPP) is a chronic and potentially life-threatening inflammatory disease characterized by recurrent, sudden flares often accompanied by systemic symptoms. With the introduction of new, targeted therapies for GPP there is an increased need to better understand patient characteristics to improve disease management. Objectives: To assess the epidemiology of GPP, and compare clinical characteristics, treatments and overall survival between GPP and population-based controls and control participants with psoriasis vulgaris. Furthermore, flare occurrence and risk factors for flares were also assessed. Methods: All Finnish patients with ≥1 GPP diagnosis (International Classification of Diseases, Tenth Revision: L40.1) in secondary healthcare between 1996 and 2021 and age- and sex-matched control groups were identified. Data on diagnoses, medications and deaths were collected from national registers. Incidence and prevalence were assessed using different case criteria. The primary analysis group included patients with ≥2 GPP diagnoses at a dermatology clinic in specialty care. Results: GPP period prevalence decreased from 9.9 to 4.7 and the incidence rate from 4.2 to 2.1 per 100 000 when using stricter case criteria. Psoriasis (73%) and hypertension (49%) were the most common comorbidities among patients with GPP, and topical corticosteroids were the most used medication (92%; Conclusions: The epidemiology of GPP in Finland was found to be comparable to previously published estimates and associated with a high disease burden and shorter overall survival. Flares occurred frequently during follow-up and are associated with an increased risk of death. Standardized guidelines are crucial to improve the timely diagnosis and management of the disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.